Abstract:Cancer cells are constantly evolving to adapt to environmental changes, particularly during exposure to drug treatment. In this work, we aimed to characterize genetic and epigenetic changes in mitochondrial DNA (mtDNA) that may increase the resistance of oral squamous cell carcinoma (OSCC) to cisplatin. We first derived drug-resistant cells from two human OSCC cell lines, namely SAS and H103, by continual cisplatin treatments for about 4 months. To determine mtDNA changes induced by cisplatin, we performed nanopore sequencing and quantitative polymerase chain reaction analysis of mtDNA extracted from the cells pre- and post-treatment. We also assessed the mitochondrial functions of the cells and their capacity to generate intracellular reactive oxygen species (ROS). We found that in the cisplatin-resistant cells derived from SAS, there was a reduction in mtDNA content and significant enrichment of a m.3910G > C mutation in the MT-ND1 gene. However, such changes were not detected in cisplatin-resistant H103 cells. The cisplatin treatment also altered methylation patterns in both SAS and H103 cells and decreased their sensitivity to ROS-induced cytotoxicity. We suggest that the sequence alterations and epigenetic changes in mtDNA and the reduction in mtDNA content could be key drivers of cisplatin resistance in OSCC. These mtDNA alterations may participate in cellular adaptation that serves as a response to adverse changes in the environment, particularly exposure to cytotoxic agents. Importantly, the observed mtDNA changes may be influenced by the distinct genetic landscapes of various cancer subtypes. Overall, this study reveals significant insights into cisplatin resistance driven by complex mtDNA dynamics, particularly in OSCC. This underscores the need for targeted therapies tailored to the genetic profiles of individual OSCC patients to improve disease prognosis.

Research progress on the relationship between mitochondrial function and oral squamous cell carcinoma

Roles of Mitochondria in Oral Squamous Cell Carcinoma Therapy: Friend or Foe?

The Role of Mitochondrial Dynamics and Mitophagy in Carcinogenesis, Metastasis and Therapy.

Relationship of Mitochondrial-Related Protein Expression with the Differentiation, Metastasis, and Poor Prognosis of Oral Squamous Cell Carcinoma

Research Progress on Mitochondria Regulating Tumor Immunity.

Potential role of heteroplasmic mitochondrial DNA mutations in modulating the subtype-specific adaptation of oral squamous cell carcinoma to cisplatin therapy

Mitochondria-Shaping Proteins and Chemotherapy

The effect of m6A methyltransferase METTL3 mediated TMEM30A regulation on tumor energy metabolism and cisplatin anti-tumor activity in oral squamous cell carcinoma

Targeting mitochondria: a novel approach for treating platinum-resistant ovarian cancer

MAPK Signaling Pathway in Oral Squamous Cell Carcinoma: Biological Function and Targeted Therapy

Mitochondrial impairment and downregulation of Drp1 phosphorylation underlie the antiproliferative and proapoptotic effects of alantolactone on oral squamous cell carcinoma cells

Current trends of targeted therapy for oral squamous cell carcinoma

Research progress on cell cycle regulation-related molecules in the development of oral squamous cell carcinoma

Mitochondrial integration and ovarian cancer chemotherapy resistance

Role of oral microbiome in oral oncogenesis, tumor progression, and metastasis

Mitochondrial DNA sequences and transcriptomic profiles for elucidating the genetic underpinnings of cisplatin responsiveness in oral squamous cell carcinoma

Advances of antineoplastic agents based on mitochondrial targeting mechanism

Progress of Nanomaterials-Based Photothermal Therapy for Oral Squamous Cell Carcinoma

Application of Natural Medicinal Plants Active Ingredients in Oral Squamous Cell Carcinoma

The role of mitochondria in tumor metastasis and advances in mitochondria-targeted cancer therapy

Advances in the Histone Acetylation Modification in the Oral Squamous Cell Carcinoma